Abstract
Objective: Carcinosarcoma of the ovary and uterus represent rare, highly aggressive malignancies associated with poor survival outcomes. PARP inhibitors represent novel treatment options for cancers with underlying impaired DNA repair via homologous recombination mechanisms. We used whole exome sequencing (WES) data from a large cohort of carcinosarcoma patients to investigate whether ovarian (OCS) and uterine carcinosarcoma (UCS) possess the mutational signature of homologous recombination deficiency (HRD) and whether there may be a role for HRD-directed therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
